SAFETY AND EFFICACY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A 4-WEEK PHASE II A DOSE RANGING, MULTI-CENTER TRIAL

被引：0
|
作者：
Vanhoutte, F. P. [1 ]
Van der Aa, A. [1 ]
Meuleners, L. [1 ]
van 't Klooster, G. [1 ]
机构：
[1] Galapagos NV, Mechelen, Belgium
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：242 / 242
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR, AFTER SHORT-TERM TREATMENT OF RHEUMATOID ARTHRITIS; RESULTS OF A PHASE IIA TRIAL
    Vanhoutte, F. P.
    Mazur, M.
    Namour, F.
    van der Aa, A.
    Wigerinck, P.
    van 't Klooster, G. A. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 145 - 145
  • [2] The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity In Patients With Moderate To Severe Rheumatoid Arthritis; Results Of a 4-Week Dose Ranging Study
    Tasset, Chantal
    Harrison, Pille
    Van der Aa, Annegret
    Meuleners, Luc
    Vanhoutte, Frederic
    van 't Klooster, Gerben
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1018 - S1018
  • [3] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Kavanaugh, Arthur
    Ponce, Lucia
    Cseuz, Regina
    Reshetko, Olga
    Stanislavchuk, Mykola A.
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [4] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE AS MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
    Kavanaugh, A.
    Ponce, L.
    Cseuz, R.
    Reshetko, O.
    Stanislavchuk, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 247 - 247
  • [5] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Westhovens, R.
    Alten, Rieke
    Pavlova, Dace
    Enriquez-Sosa, Favio
    Mazur, Minodora
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [6] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
    Westhovens, R.
    Alten, R.
    Pavlova, D.
    Sosa, F. E. Enriquez
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 142 - 142
  • [7] 4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL
    Galien, Rene
    Harrison, Pille
    Brys, Reginald
    Van der Aa, Annegret
    van't Klooster, Gerben
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
    Florence Namour
    Paul Matthias Diderichsen
    Eugène Cox
    Béatrice Vayssière
    Annegret Van der Aa
    Chantal Tasset
    Gerben Van‘t Klooster
    Clinical Pharmacokinetics, 2015, 54 : 859 - 874
  • [9] Selective JAK1 Inhibition with Filgotinib (GLPG0634) Decreases Plasma Markers of Inflammation and Joint Damage in Patients with Rheumatoid Arthritis
    Galien, Rene
    Van der Aa, Annegret
    Blanque, Roland
    Darquenne, Sophie
    Harrison, Pille
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [10] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
    Namour, Florence
    Diderichsen, Paul Matthias
    Cox, Eugene
    Vayssiere, Beatrice
    Van der Aa, Annegret
    Tasset, Chantal
    Van't Klooster, Gerben
    CLINICAL PHARMACOKINETICS, 2015, 54 (08) : 859 - 874
12345